North Chesterfield opioid addiction treatment company Indivior PLC is moving toward an additional listing on the Nasdaq Stock Exchange.
Executives with the company, which is already listed on the London Stock Exchange, said Thursday the move is aimed at bringing the company a greater profile. In March, it closed on a $145 million acquisition of Opiant Pharmaceuticals Inc., a company developing a new opioid overdose treatment that’s stronger than Narcan.
Indivior plans to be listed on the Nasdaq…
